Zimbabwe has rejected a major US health deal valued at 367 million US dollars (£272m) over five years because of Washington's request for confidential data.
This rejection became public following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "skewed".
An official representative later stated that the United States was requesting biological samples for research and commercial purposes but refused to guarantee the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more talks to reach a agreement agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development follows a similar case in Kenya, where a court suspended a related deal with the US after legal challenges were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and accountability.
As per statements, Sixteen nations in Africa have to date signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Effectively, our country would supply the basic resources for medical research with no assurance that the final treatments would be available to our people should a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems already established via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This system is intended to guarantee that when a country provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation might be arranged in a way that respects the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but suggested that negotiations should continue considering much of the nation's HIV programmes relied on international support.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
The halted deal emphasises the continuing debate between accepting vital foreign assistance and protecting local interests in an ever more interconnected world.